# Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

> **NCT02577315** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Metformin
- **DRUG:** Empagliflozin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02577315
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577315, "Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02577315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*